Certara (CERT) Q4 2025: Software Revenue Up 10% as Execution Focus Sharpens for 2026
Certara’s new CEO is pressing for sharper execution after a year where software revenue grew but bookings lagged, exposing internal and market-driven friction. The company is doubling down on AI-enabled drug development platforms and cost discipline, signaling a transition year with flat to modest growth as it retools for a more scalable, customer-centric model. Investors should watch for operational improvements and regulatory tailwinds to translate into sustainable double-digit growth targets in 2027 and beyond.
Summary
- Execution Reset Underway: New leadership is prioritizing operational discipline and portfolio focus to unlock growth.
- AI Integration Accelerates: Product launches and R&D investments target deeper AI embedding in core platforms.
- 2026 as Transition Year: Modest growth guidance reflects both market stability and internal improvement initiatives.
Performance Analysis
Certara delivered 3% year-over-year revenue growth in Q4, with software revenue up 10% and services revenue down 1%. Full-year results were stronger, showing 9% growth, but the quarter exposed a clear gap between top-line expansion and underlying bookings momentum, especially in software. The company’s core MIDD (Model-Informed Drug Development) software and Pinnacle 21, regulatory data validation tool, led the software gains, while organic software growth landed at 7% after adjusting for the ChemAxon acquisition.
However, software bookings fell 6% in Q4, reflecting both market headwinds—such as big pharma reprioritizations and fewer clinical studies—and internal execution gaps in pipeline conversion. Services saw mixed trends: while regulatory writing bookings rebounded, overall services revenue remained flat, weighed down by market volatility and past pipeline disruptions. Adjusted EBITDA margin held steady at 31% for the quarter, but net income swung to a loss, reflecting higher R&D and operating costs tied to innovation investments.
- Bookings Weakness in Software: Pipeline conversion and customer delays led to a drop in new and renewal bookings, particularly among larger clients.
- Services Bookings Surge in December: Late-quarter discretionary spend from customers drove a notable uptick, hinting at possible demand stabilization.
- Cost Structure Pressured by R&D: Increased investment in product development and AI initiatives weighed on net income despite stable EBITDA margins.
The disconnect between software revenue growth and bookings signals a need for sharper go-to-market execution and improved alignment between R&D spend and commercial outcomes. The company’s focus on AI-driven product launches and operational discipline will be critical to restoring growth momentum in 2026.
Executive Commentary
"We must operate with greater focus. We must build with clear priorities and reliable execution. We must engage customers more proactively. And we must create a culture of accountability and financial discipline. Simply put, to grow faster, Certara must run differently. And as CEO, I intend to lead that change with urgency and clarity."
John Resnick, Chief Executive Officer
"Our operating plan contemplates discretionary investments in research and development related to product development initiatives, as well as minor investments in G&A and cost of sales. As John mentioned in his remarks, we have identified upwards of $10 million in cost avoidance in 2026 versus the prior planning."
John Gallagher, Chief Financial Officer
Strategic Positioning
1. AI-Enabled Platform Expansion
Certara is embedding AI across its core software and services portfolio, with new product launches like Certara IQ in QSP (Quantitative Systems Pharmacology) and expanded AI modules in Phoenix, its pharmacokinetic modeling tool. These investments aim to accelerate drug development, improve trial design, and unlock new use cases across preclinical and clinical workflows.
2. Customer-Centric Operating Model
The new CEO is driving a shift toward deeper customer engagement and senior-level involvement. The company is leveraging client feedback to inform product roadmaps, prioritize AI initiatives, and refine commercial strategies. This approach is designed to build stickier relationships and better align product value with pricing, especially as clients seek partners to navigate regulatory changes and cost pressures.
3. Operational Discipline and Cost Management
Certara is targeting $10 million in cost avoidance for 2026, focusing on pricing optimization, improved delivery, and increased returns from sales and R&D investments. The company is also reviewing its regulatory writing and operations business for potential divestiture, aiming to redeploy capital toward higher-growth areas.
4. Strategic Portfolio Focus
The company is doubling down on its four core franchises, which are deeply embedded in customer workflows and used by 23 regulatory agencies globally. The integration of ChemAxon and continued investment in MIDD are central to the strategy, as is selectively expanding into adjacent areas like early-stage drug discovery where computational modeling can drive outsized value.
Key Considerations
Certara’s 2025 performance highlighted both the resilience of its core franchises and the urgency for operational change. The leadership transition brings a renewed focus on execution, cost control, and customer intimacy, but the path to sustainable double-digit growth will require bridging the gap between innovation investment and commercial outcomes.
Key Considerations:
- Execution Gaps Exposed: Slower pipeline conversion and missed software bookings underscore the need for stronger sales processes and commercial discipline.
- AI as Growth Catalyst: Accelerated AI integration is expected to drive both product differentiation and operational efficiency, but the commercial impact must be proven.
- Regulatory Tailwinds Emerging: Regulatory agencies are increasingly endorsing computational and model-informed approaches, creating a favorable backdrop for Certara’s offerings.
- Portfolio Rationalization Ongoing: The pending outcome of the regulatory writing business review could reshape capital allocation and strategic focus.
Risks
Certara faces risks from macro-driven pharma spending volatility, delayed clinical trial activity, and customer reprioritizations that can impact software and services bookings. Execution risk remains high as the company undertakes operational changes and portfolio optimization. The transition year guidance reflects both market caution and the need to prove that cost discipline and AI investments will translate into durable growth. Regulatory shifts, while favorable, may take time to materially impact adoption and revenue.
Forward Outlook
For Q1 2026, Certara guided to:
- Revenue at the low end of the flat to 4% annual growth range, reflecting tough prior-year comparisons.
- Adjusted EBITDA margin expected to be lower in the first half, rising in the second half as operational improvements take hold.
For full-year 2026, management maintained guidance:
- Revenue growth of flat to 4% over 2025
- Adjusted EBITDA margin between 30% and 32%
- Adjusted EPS in the range of $0.44 to $0.48 per share
Management emphasized:
- 2026 as a “transition year” with a focus on operational discipline, cost avoidance, and strategic investment in AI and R&D.
- Multi-year double-digit growth targets will be detailed later in 2026 as improvements are implemented and market conditions stabilize.
Takeaways
Certara’s 2025 results reveal a business with strong embedded assets but a clear imperative to translate innovation and market opportunity into consistent growth. The leadership reset, AI acceleration, and focus on operational discipline set the stage for a more scalable, customer-centric model, but the proof will be in improved bookings and margin trajectory as 2026 unfolds.
- Execution Remains the Critical Lever: Software bookings softness and services volatility highlight the need for sharper commercial focus and disciplined investment allocation.
- AI and Regulatory Trends Are Tailwinds: Product launches and regulatory endorsements create a favorable environment, but Certara must demonstrate that these translate into real revenue and margin gains.
- 2026 Is a Pivotal Transition Year: Investors should monitor progress on cost avoidance, customer engagement, and the outcome of the regulatory writing business review as signals of future trajectory.
Conclusion
Certara enters 2026 with a renewed operational mandate and a sharpened focus on AI-enabled growth, but the company must close the gap between innovation and execution to achieve its double-digit growth ambitions. The market opportunity remains compelling, yet investors should expect a year of foundational work before material acceleration.
Industry Read-Through
Certara’s results and commentary reflect a broader life sciences trend: regulatory acceptance of computational and model-informed drug development is accelerating, creating new opportunities for technology providers with deep scientific and workflow integration. The bookings volatility and customer reprioritizations seen here are mirrored across the CRO (Contract Research Organization) and pharma tech landscape, underscoring the importance of execution, differentiated data assets, and AI capabilities. As regulatory agencies push for innovation in trial design and cost reduction, vendors able to bridge R&D, software, and services with proven outcomes will be best positioned to capture share in a still-fragmented market.